Suppr超能文献

齐多夫定耐药的1型人类免疫缺陷病毒分离株在体外的相对复制适应性

Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro.

作者信息

Harrigan P R, Bloor S, Larder B A

机构信息

Clinical Virology, Glaxo Wellcome Research and Development, Stevenage, United Kingdom.

出版信息

J Virol. 1998 May;72(5):3773-8. doi: 10.1128/JVI.72.5.3773-3778.1998.

Abstract

Replication of mixtures of two or more human immunodeficiency virus type 1 (HIV-1) variants would be expected to result in the eventual selection of the fittest virus due to Darwinian competition among the variants. The relative proportions of known HIV-1 variants (which may differ only by a single nucleotide from a standard "wild-type" virus, HIV-1HXB2) in mixed viral cultures were quantified by analysis of automated sequence signals of reverse transcriptase PCR products. With this method, the relative levels of replicative fitness of several zidovudine (3'-azidothymidine)-resistant HIV-1HXB2 variants were estimated under controlled in vitro conditions by measuring the rate of change in the proportions of viral variants as they replicated in cell cultures both in the presence and in the absence of drug selection pressure. These variants were engineered to contain commonly observed zidovudine resistance mutations in the HIV-1 reverse transcriptase (M41L, K70R, T215Y, and M41L+T215Y). In the absence of zidovudine, all variants tested displayed reduced replicative fitness compared to wild-type HIV-1HXB2. The order of relative fitness was wild type > K70R >> T215Y = M41L+T215Y > M41L. Mixed cultures in the presence of zidovudine showed a dose-dependent selection pressure against the wild-type virus which varied according to the resistance profile of each virus. The information gathered from this approach provides insight into competition among multiple HIV-1 variants, which likely occurs in vivo with drug selection pressure, and may be applicable in more complex mathematical models for predicting the emergence of HIV-1 variants after the initiation of antiretroviral therapy.

摘要

由于1型人类免疫缺陷病毒(HIV-1)变体之间存在达尔文式竞争,预计两种或更多HIV-1变体的混合物复制最终会导致最适应病毒的选择。通过分析逆转录酶PCR产物的自动序列信号,对混合病毒培养物中已知HIV-1变体(可能与标准“野生型”病毒HIV-1HXB2仅相差一个核苷酸)的相对比例进行了定量。使用这种方法,通过测量病毒变体在有和没有药物选择压力的情况下在细胞培养物中复制时其比例的变化率,在受控的体外条件下估计了几种齐多夫定(3'-叠氮胸苷)抗性HIV-1HXB2变体的相对复制适应度水平。这些变体经过工程改造,在HIV-1逆转录酶中含有常见的齐多夫定抗性突变(M41L、K70R、T215Y和M41L+T215Y)。在没有齐多夫定的情况下,与野生型HIV-1HXB2相比,所有测试的变体都显示出复制适应度降低。相对适应度的顺序为野生型>K70R>>T215Y = M41L+T215Y>M41L。在有齐多夫定的情况下进行的混合培养显示出针对野生型病毒的剂量依赖性选择压力,该压力根据每种病毒的抗性谱而有所不同。从这种方法收集的信息提供了对多种HIV-1变体之间竞争的深入了解,这种竞争可能在体内存在药物选择压力的情况下发生,并且可能适用于更复杂的数学模型,以预测抗逆转录病毒治疗开始后HIV-1变体的出现。

相似文献

引用本文的文献

2
The Effects of Population Size Histories on Estimates of Selection Coefficients from Time-Series Genetic Data.
Mol Biol Evol. 2016 Nov;33(11):3002-3027. doi: 10.1093/molbev/msw173. Epub 2016 Aug 22.
3
Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy.
Antiviral Res. 2016 Feb;126:90-8. doi: 10.1016/j.antiviral.2015.12.007. Epub 2015 Dec 22.
4
Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):487-94. doi: 10.1097/QAI.0000000000000524.
5
Estimating HIV-1 fitness characteristics from cross-sectional genotype data.
PLoS Comput Biol. 2014 Nov 6;10(11):e1003886. doi: 10.1371/journal.pcbi.1003886. eCollection 2014 Nov.
6
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
Curr Opin Virol. 2013 Apr;3(2):119-28. doi: 10.1016/j.coviro.2013.03.014. Epub 2013 Apr 19.
7
Lipid Peroxidation Correlates with HIVmRNA in Serodiscordant Heterosexual HIVpartners of Nigerian Origin.
Indian J Clin Biochem. 2011 Jul;26(3):249-56. doi: 10.1007/s12291-011-0120-8. Epub 2011 Feb 18.
8
Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.
J Virol. 2011 Jul;85(13):6403-15. doi: 10.1128/JVI.02389-10. Epub 2011 Apr 13.
9
Fitness ranking of individual mutants drives patterns of epistatic interactions in HIV-1.
PLoS One. 2011 Mar 31;6(3):e18375. doi: 10.1371/journal.pone.0018375.

本文引用的文献

2
Human immunodeficiency virus type 1 protease inhibitors.
Arch Intern Med. 1997 May 12;157(9):951-9.
3
Clinical significance of drug resistance in HIV-1 infection.
AIDS. 1996 Dec;10 Suppl 5:S27-31. doi: 10.1097/00002030-199612005-00005.
4
Reverse transcriptase fidelity and HIV-1 variation.
Science. 1997 Jan 10;275(5297):229-30; author reply 230-1.
8
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
Science. 1996 Mar 15;271(5255):1582-6. doi: 10.1126/science.271.5255.1582.
9
Viral resistance and the selection of antiretroviral combinations.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S28-33.
10
Quantitation of human immunodeficiency virus type 1 infection kinetics.
J Virol. 1993 Apr;67(4):2182-90. doi: 10.1128/JVI.67.4.2182-2190.1993.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验